MarketPulse

dupilumab

6 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Sanofi And Regeneron

Sanofi and Regeneron Win FDA Nod for Dupixent in Young Children With Chronic Urticaria

FDA approves Dupixent for children ages 2-11 with chronic spontaneous urticaria, marking first biologic treatment for this pediatric population.
SNYREGNchronic spontaneous urticariaFDA approval
GlobeNewswire Inc.GlobeNewswire Inc.··Sanofi And Regeneron

Dupixent Wins FDA Nod for Young Children With Chronic Urticaria, Expanding Market Reach

FDA approves Dupixent for children ages 2-11 with uncontrolled chronic spontaneous urticaria, marking first biologic treatment for this pediatric population.
SNYREGNchronic spontaneous urticariaFDA approval
GlobeNewswire Inc.GlobeNewswire Inc.··Sanofi/Regeneron

Sanofi, Regeneron Win EU Approval for Dupixent in Pediatric Chronic Urticaria

Sanofi and Regeneron win EU approval for Dupixent as first targeted therapy for chronic urticaria in children ages 2-11, expanding the blockbuster drug's market reach.
SNYREGNDupixentdupilumab
GlobeNewswire Inc.GlobeNewswire Inc.··Sanofi And Regeneron

Sanofi, Regeneron Win EU Nod for Dupixent in Young Children with Chronic Urticaria

Dupixent gains European approval for treating moderate-to-severe chronic spontaneous urticaria in children ages 2-11, expanding the drug's pediatric portfolio.
SNYREGNchronic spontaneous urticariaDupixent
GlobeNewswire Inc.GlobeNewswire Inc.··Sanofi And Regeneron

Sanofi and Regeneron's Dupixent Wins Japan Approval for Rare Skin Disorder

Dupixent receives Japanese marketing authorization for bullous pemphigoid, becoming the first targeted treatment. Study showed 18% remission rate versus 4% for placebo.
SNYREGNmonoclonal antibodyclinical trial
GlobeNewswire Inc.GlobeNewswire Inc.··Sanofi And Regeneron

Dupixent Wins Japan Approval for Rare Autoimmune Disorder, Expanding Sanofi-Regeneron Pipeline

Sanofi and Regeneron's Dupixent secured Japanese regulatory approval for bullous pemphigoid, marking the drug's seventh indication in Japan with superior remission rates versus placebo.
SNYREGNclinical trialDupixent